CuroTis is an innovative StartUp that aims to lead the development of the next generation of body-own regenerative medicine and has therefore developed the XSGraft.

Renal and vascular diseases are among the leading causes of death worldwide and maintaining vascular access is critical to the for survival of patients suffering from these conditions. However, almost daily cannulations damage the patient’s blood vessels, and eventually even synthetic grafts can no longer be used to provide vascular access.
A key challenge in vascular graft development is to create a graft that closely mimics the natural properties of human blood vessels. 

The XSGraft is an implant which stimulates the body to grow vascular tissue at the target site that can be used for various applications. The initial application is in the cardiovascular field where the created tissue in the shape of a tube is grafted in the vasculature. site. Within four weeks post-grafting, a new, disease-free blood vessel forms, endowed with elastin and a functional endothelial layer. With this solution patients requiring vascular access e.g. for injections or dialysis treatment will obtain a regenerative, body-own vascular graft.

CuroTis is the tradename of VACIS B.V.

CuroTis

Kenneth Messier

This department provides strategic direction and oversight for the organization's operations and regulatory compliance.

CuroTis

Org chart

Teams

Executive Leadership

Offices

CuroTis

Org chart

Teams

Executive Leadership

Offices

Related companies